By Adam Clark

 

AstraZeneca PLC (AZN.LN) said Monday that its Selumetinib drug has been granted a breakthrough therapy designation in the U.S. for neurofibromatosis type 1, a genetic condition which causes tumors to grow in the nervous system.

The drug company said the designation is for treatment of pediatric patients aged three years and older, and means Selumetinib could get an expedited regulatory review.

The designation is based on a phase 2 trial for Selumetinib. The drug is being jointly developed by AstraZeneca and Merck & Co. Inc. (MRK).

 

Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones

 

(END) Dow Jones Newswires

April 01, 2019 02:25 ET (06:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AstraZeneca Charts.